LegoChem partners Glycotope to develop antibody-drug conjugate
Pharmaceutical Technology
OCTOBER 17, 2023
LegoChem Biosciences has entered an exclusive worldwide licensing agreement with Glycotope to develop an antibody-drug conjugate (ADC).
Sterling Pharma Solutions Granted MIA (IMP) License by MHRA for cGMP Antibody-Drug Conjugate Manufacturing at its Facility in Deeside, UK
Pharma Mirror
APRIL 18, 2023
The license allows Sterling to manufacture antibody-drug conjugates (ADCs) for clinical use in its current Good Manufacturing Practices (cGMP) compliant manufacturing facility in Deeside, UK.
Licensing 
130
130 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ASCO puts spotlight on advancing antibody-drug conjugate pipeline
Bio Pharma Dive
MAY 25, 2023
Study abstracts released Thursday give investors and analysts a better look at cancer treatments recently licensed by Merck and BioNTech as well as fresh details on other closely watched ADC candidates.
Antibody 321
321 
Adcendo licenses Multitude anti-TF ADC in $1bn+ deal
pharmaphorum
AUGUST 20, 2024
Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in various forms of cancer.Copenhagen-based Adcendo is paying what is rumours to be tens of millions of dollars in upfront fees for rights to Multitude's anti-tissue factor (..)
Licensing 78
78 
Avidity, Kymera raise fresh funds; Walgreens partners with BARDA
Bio Pharma Dive
AUGUST 20, 2024
In addition to new stock offerings, this week saw Merck license an antibody drug conjugate and BARDA further work trying to innovate remote clinical trials.
Licensing 144
144 
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
Bio Pharma Dive
JUNE 21, 2024
Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead. A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study.
Licensing 167
167 
LegoChem, Amgen partner to develop antibody drug conjugates
Pharmaceutical Technology
DECEMBER 26, 2022
LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). Till date, the company has signed a total of 12 ADC licensing deals, worth more than $5bn.
Antibody 130
130 
BioNTech licenses bispecific antibody for cancer in $1 billion deal
BioPharma Reporter
NOVEMBER 7, 2023
The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech companyâs bispecific antibody cancer drug PM8002 in all territories except for Greater China.
Antibody 98
98 
AstraZeneca to deliver Covid-19 antibody therapy doses to Switzerland
Pharmaceutical Technology
JULY 21, 2022
AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.
Antibody 264
264 
AbbVie announces acquisition of DJS Antibodies for $255m
Pharmaceutical Technology
OCTOBER 21, 2022
AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).
Antibody 217
217 
Corbus and CSPC Megalith sign licence agreement for antibody drug conjugate
Pharmaceutical Technology
FEBRUARY 14, 2023
Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for CRB-701.
Antibody 130
130 
Biogen licenses Denali’s amyloid beta programme for Alzheimer’s
Pharmaceutical Technology
APRIL 13, 2023
Biogen has exercised an option to license Denali Therapeutics ’ (Denali) programme to develop immunotherapies for the treatment of Alzheimer’s disease. ATV: Aβ uses Denali’s ATV technology to cross the blood-brain barrier (BBB) and increase brain exposure to antibodies.
Licensing 130
130 
US FDA approves Eisai-Biogen’s antibody for Alzheimer’s
Pharmaceutical Technology
JANUARY 9, 2023
Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.
FDA Approval 246
246 
AstraZeneca adds to rare disease drug pipeline with Neurimmune deal
Bio Pharma Dive
JANUARY 7, 2022
Neurimmune, which will license to AstraZeneca an early-stage treatment for a rare form of cardiomyopathy, is probably best known for its invention of the antibody that became Biogen's Alzheimer's drug Aduhelm.
Drugs 293
293 
Three trends in the antibody-drug conjugate (ADC) marketÂ
Drug Discovery World
JUNE 1, 2023
Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. Financing When it comes to looking to the future in the drug discovery industry, an important question to ask is: Where is the money?
Antibody 98
98 
Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China
Pharmaceutical Technology
JULY 4, 2022
Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.
Antibody 279
279 
Renaissance Pharma licenses Hu14.18 for neuroblastoma
Drug Discovery World
AUGUST 2, 2023
Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. ” The post Renaissance Pharma licenses Hu14.18
Licensing 98
98 
Partnership could enhance antibody discovery for cancer research
Drug Discovery World
JULY 21, 2023
Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. The post Partnership could enhance antibody discovery for cancer research appeared first on Drug Discovery World (DDW).
Antibody 98
98 
Syncromune and Eucure enter antibody licence deal
Pharmaceutical Technology
OCTOBER 19, 2022
Syncromune and Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma have entered an exclusive global licence agreement for OX40 antibody YH002 and two other active ingredients. . Eucure will oversee the production and delivery of the drug, while Syncromune will handle the clinical development and marketing.
Antibody 130
130 
Ipsen licenses ‘cutting-edge’ ADC from Sutro Biopharma in $900m deal
BioPharma Reporter
APRIL 2, 2024
Ipsen is expanding its oncology pipeline by securing the global licensing rights to an antibody-drug conjugate (ADC) for solid tumors from Sutro Biopharma, its first drug in the category.
Licensing 52
52 
Adcendo and Duality Biologics sign license deal for ADC platform
Pharmaceutical Technology
JANUARY 6, 2023
Danish biotech company Adcendo has entered into a licence agreement with Duality Biologics on the next-generation antibody-drug conjugates (ADC) platform. The post Adcendo and Duality Biologics sign license deal for ADC platform appeared first on Pharmaceutical Technology.
Licensing 130
130 
Antibody fragment-based drug could slow geographic atrophy
Drug Discovery World
AUGUST 4, 2023
CDR-Life has reached a development milestone with its antibody fragment-based drug candidate that could significantly slow down the progression of geographic atrophy (GA). The company’s first of several therapeutic candidates in development, CDR404, targets MAGE-A4 and is anticipated to enter the clinic in 2024.
Antibody 52
52 
Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal
BioSpace
DECEMBER 21, 2022
Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.
Licensing 76
76 
US FDA grants fast track designation for Jasper’s antibody to treat SCID
Pharmaceutical Technology
SEPTEMBER 16, 2022
The US Food and Drug Administration (FDA) has granted fast track designation to Jasper Therapeutics’ antibody, JSP191, for the treatment of severe combined immunodeficiency (SCID) patients who undergo allogeneic hematopoietic stem cell transplant. .
Antibody 130
130 
ADC licensing deals reached peak of $16.6 billion in 2022
BioPharma Reporter
OCTOBER 26, 2023
The biopharmaceutical industry witnessed a 400% growth in total deal value of antibody-drug conjugate (ADC) licensing agreements from 2017-2022 and reached a peak of $16.6 billion in 2022, reveals data and analytics company GlobalData.
Licensing 59
59 
New class of antibody cancer drug shows promise
Drug Discovery World
JULY 26, 2023
A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at King’s College London. The drug, MOv18 IgE, was developed by researchers at King’s College London.
Antibody 52
52 
This week in drug discovery (12-16 August)Â
Drug Discovery World
AUGUST 16, 2024
The chosen news highlights this week all feature advances in drug development in oncology indications and reflect the breadth of therapeutic approaches to cancer treatment. monoclonal antibody. The post This week in drug discovery (12-16 August) appeared first on Drug Discovery World (DDW). First claudin 18.2
Drugs 59
59 
Iksuda Therapeutics Deepens Clinical Pipeline Through Licensing Agreement for Her2 Antibody Drug Conjugate Programme From LegoChem Biosciences
BioTech 365
JANUARY 10, 2022
Iksuda Therapeutics Deepens Clinical Pipeline Through Licensing Agreement for Her2 Antibody Drug Conjugate Programme From LegoChem Biosciences Iksuda Therapeutics Deepens Clinical Pipeline Through Licensing Agreement for Her2 Antibody Drug Conjugate Programme From LegoChem Biosciences US phase 1 study expected to … Continue reading →
Licensing 52
52 
LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates
BioTech 365
JUNE 22, 2021
LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates Expanded agreement grants Iksuda access to LegoChem Biosciences’ next generation ADC platform for up … Continue reading (..)
Licensing 52
52 
Advancing antibody discovery with AI
Drug Discovery World
NOVEMBER 2, 2023
DenovAI is the second start-up to launch from the global pharma consortium AION Labs – an organisation that aims to improve the drug discovery and development process through the use of AI and other computational technologies. RA: How laborious and expensive are current antibody discovery efforts? KS: In short, incredibly so.
Antibody 83
83 
License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed
The Pharma Data
MARCH 31, 2023
AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc. i for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, Notes CMG901 CMG901 is a novel antibody drug conjugate targeting Claudin 18.2, a promising therapeutic target in gastric cancers.
Licensing 40
40 
AstraZeneca buys into startup RQ Bio’s COVID antibodies
pharmaphorum
MAY 18, 2022
Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended to protect vulnerable and immunosuppressed people from COVID-19. ” The post AstraZeneca buys into startup RQ Bio’s COVID antibodies appeared first on. .
Antibody 98
98 
Synaffix secures additional ADC technology licensing deals
BioPharma Reporter
JANUARY 6, 2023
Synaffix, a Netherlands based company providing clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has signed off on two new licensing deals this week.
Licensing 52
52 Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy
BioTech 365
OCTOBER 21, 2021
Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy … Continue reading →
Licensing 52
52 
Exploring the Miracle Antibody Drug Conjugate Technologies
Roots Analysis
JANUARY 21, 2024
With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. In this context, the role of the linker molecule and the conjugation technology used is pivotal.
Antibody 40
40 
Efficiently develop antibody-based therapeutics
Drug Discovery World
OCTOBER 12, 2022
In the Quality by Design (QbD) approach to antibody-based therapeutics development, stability characterisation —the probability of a protein unfolding or denaturing— is performed to ensure that structure and function are preserved throughout development and manufacturing. . Approaches for monoclonal antibody formulation .
Antibody 52
52 
Fierce Pharma Asia—AstraZeneca's GLP-1 play; Takeda's cancer drug approval; BioNTech's bispecific deal
Fierce Pharma
NOVEMBER 9, 2023
AstraZeneca licensed an oral GLP-1 agonist from China's Eccogene. Takeda won FDA approval for the Hutchmed-developed colorectal cancer drug Fruzaqla. AstraZeneca licensed an oral GLP-1 agonist from China's Eccogene. Takeda won FDA approval for Hutchmed-developed colorectal cancer drug Fruzaqla.
FDA Approval 84
84 
Let's personalize your content